Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 426
Filtrar
1.
Acta Virol ; 63(3): 309-315, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31507197

RESUMEN

Influenza virus is activated by proteolytic cleavage of hemagglutinin by trypsin. After determining the optimal trypsin concentration, intracellular and extracellular influenza A/PR/8/34 (H1N1) and A/Victoria/361/2011 (H3N2) virus productions were compared in cultures treated with T-705 (favipiravir) and GS 4071 (an active form of oseltamivir). Although both drugs efficiently inhibited extracellular viral RNA release in a dose-dependent manner, T-705 inhibited it to the level of the inoculum without trypsin treatment, while GS 4071 inhibited it to a final level 10 times higher than that without trypsin. T-705 inhibited intracellular viral RNA production to the level of input virus in both trypsin-treated and untreated cells. In contrast, GS 4071 dose-dependently inhibited intracellular viral RNA production in cells treated with trypsin but allowed viral RNA synthesis. The level of maximum inhibition by GS 4071was 10 times higher than that of cells without trypsin and 1,000 times greater than the inoculum titer in cells without trypsin. T-705 inhibited both intracellular and extracellular virus production 1,000 and 10 times more strongly, respectively, than GS 4071. T-705 has powerful anti-influenza activity in the absence of trypsin and even in the trypsin-optimized growth condition, suggesting the therapeutic advantage in treatment of influenza complicated with bacterial pneumonia. Keywords: influenza; T-705; Tamiflu; trypsin; bacterial trypsin-like protease.


Asunto(s)
Amidas , Antivirales , Subtipo H1N1 del Virus de la Influenza A , Subtipo H3N2 del Virus de la Influenza A , Pirazinas , Tripsina , Amidas/farmacología , Antivirales/farmacología , Línea Celular , Regulación Viral de la Expresión Génica/efectos de los fármacos , Humanos , Subtipo H1N1 del Virus de la Influenza A/efectos de los fármacos , Subtipo H3N2 del Virus de la Influenza A/efectos de los fármacos , Oseltamivir/farmacología , Pirazinas/farmacología , ARN Viral/biosíntesis , Tripsina/farmacología
3.
Acta Virol ; 61(1): 48-55, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28105854

RESUMEN

Influenza virus infection induces the production of various cytokines, which play important roles in the pathogenesis of infection. Among the cytokines induced by influenza, tumor necrosis factor α (TNF-α) production has been correlated with the severity of lung lesions. We investigated the effects of T-705 (Favipiravir, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) on cytokine production due to influenza virus infection in vitro and in vivo, compared with oseltamivir or GS 4071, an active form of oseltamivir. TNF-α production in mouse macrophage-derived P388D1 cells infected with the influenza virus was lower following treatment with T-705 at concentrations of 0.3 to 100 µg/ml than treatment with GS 4071 at the same concentrations. The effect of treatment with T-705 on the cytokine production induced by the influenza virus infection was investigated in mouse influenza virus infection model. At 48 h post-infection (p.i.) T-705 significantly suppressed the viral load in the lungs and TNF-α production in the airways of infected mice even when viral loads were high. Furthermore, T-705 suppressed only TNF-α production from the early phase of infection. In this study, T-705 showed the antiviral activity of reducing pulmonary viral load compared with oseltamivir, thereby suppressing the TNF-α production. This feature of T-705 is benefit against severe influenza infection.


Asunto(s)
Amidas/uso terapéutico , Antivirales/uso terapéutico , Subtipo H1N1 del Virus de la Influenza A , Infecciones por Orthomyxoviridae/tratamiento farmacológico , Pirazinas/uso terapéutico , Factor de Necrosis Tumoral alfa/metabolismo , Animales , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/virología , Línea Celular Tumoral , Femenino , Regulación de la Expresión Génica , Ratones , Infecciones por Orthomyxoviridae/virología , Oseltamivir/uso terapéutico , Factor de Necrosis Tumoral alfa/genética , Carga Viral
4.
Nat Med ; 7(1): 88-93, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11135621

RESUMEN

Fas is the death receptor, transducing cell death signaling upon stimulation by Fas ligand. During Fas-initiated cell death signaling, the formation of Fas-death inducing signaling complex (Fas-DISC) is the first step. Here we have identified a new component of Fas-DISC which we call 'small-accelerator for death signaling' (SADS). SADS cDNA encodes a 150 amino acid polypeptide (Mr = 16,700). During Fas-mediated cell death, SADS enhances the interaction of Fas-death domain-interactive factors (FADD) and procaspase-8, and deletion mutant analysis has identified FADD- and caspase-8-interactive domains in SADS. Inhibition or removal of SADS delays Fas-mediated cell death. In addition, we demonstrate the deletion or mutation of SADS in patients with colon carcinoma and that exogenous SADS expression in human colon carcinoma SW480 cells that lack SADS leads to re-acquisition of Fas-mediated cell death. Here, we propose that SADS is one of the cell death-associated factors and enhances Fas-DISC formation, especially FADD and procaspase-8 recruitment.


Asunto(s)
Apoptosis/fisiología , Neoplasias del Colon/patología , Regulación hacia Abajo , Transducción de Señal , Receptor fas/fisiología , Secuencia de Bases , Caspasa 8 , Caspasa 9 , Caspasas/metabolismo , Neoplasias del Colon/enzimología , Neoplasias del Colon/metabolismo , Cartilla de ADN , Humanos , Unión Proteica , Receptor fas/metabolismo
7.
Acta Virol ; 53(4): 233-40, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19941386

RESUMEN

We have reported previously that an increase in interleukin 12 (IL-12) production in the lungs of mice infected with Influenza A virus or an intranasal (i.n.) administration of IL-12 to the infected mice alleviated pneumonia (Tsurita et al., J. Pharmacol. Exp. Therapeut. 298, 362-368, 2001). In this study, we found that in the bronchoalveolar lavage fluids (BALF) obtained from mice infected i.n. with Influenza A virus IL-12 was elevated on day 1 post infection (p.i.) and was followed by tumor necrosis factor alfa (TNF-alfa), IL-18, and interferons alfa, beta, and gama (IFN-alfa, -beta, and -gama) on day 2 p.i. Histochemical analyses of the infected lungs on day 1 p.i. showed the presence of IL-12 and IL-12 mRNA in mononuclear and macrophage-like cells and co-localization of macrophages with viral antigen, while other cytokines were absent. Thus, IL-12 was produced by macrophages infiltrating the infected epithelium as the first response cytokine and its production at the site of infection may direct an early immune defense to alleviate the severity of infection.


Asunto(s)
Líquido del Lavado Bronquioalveolar/inmunología , Citocinas/inmunología , Subtipo H1N1 del Virus de la Influenza A/patogenicidad , Interleucina-12/metabolismo , Pulmón/inmunología , Infecciones por Orthomyxoviridae/inmunología , Animales , Líquido del Lavado Bronquioalveolar/citología , Citocinas/metabolismo , Femenino , Subtipo H1N1 del Virus de la Influenza A/inmunología , Interleucina-12/inmunología , Leucocitos Mononucleares/inmunología , Pulmón/citología , Macrófagos/inmunología , Macrófagos/metabolismo , Ratones , Ratones Endogámicos DBA , Infecciones por Orthomyxoviridae/virología , Neumonía Viral/inmunología , Neumonía Viral/virología , ARN Mensajero/genética , ARN Mensajero/metabolismo
8.
Transplant Proc ; 50(10): 3932-3936, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30577289

RESUMEN

BACKGROUND: Cytomegalovirus (CMV) could cause rejection in immunocompromised patients during early post-renal transplant stage. The American Transplant Society guidelines recommend prophylactic therapy with ganciclovir (GCV) for 3 to 6 months to prevent CMV infections in adult renal transplant patients. However, there is no recommended CMV treatment regimen for pediatric patients. MAIN FINDINGS: We performed deceased donor kidney transplant from an anti-CMV antibody-positive donor to an anti-CMV antibody-negative 15-year-old female recipient with end-stage renal disease caused by bilateral renal hypoplasia. One month after transplant, increase in positive cells in the CMV antigenemia assay indicated a primary CMV infection in the patient, who immediately received GCV. She was switched to foscarnet after 4 months of anti-CMV therapy because of clinical GCV resistance. CMV was isolated from the peripheral blood mononuclear cells but neutralizing antibody was not detected. Isolated CMV was susceptible to GCV and foscarnet, although it carried the UL97 D605E mutation, assumed to be associated with GCV resistance. CONCLUSIONS: The primary CMV infection presented a phenotypic clinical drug resistance, but all recovered CMV isolates were drug-susceptible even if isolated after prolonged anti-CMV therapy, indicating that immune status was more important for recovery from primary CMV infection than anti-CMV therapy.


Asunto(s)
Antivirales/uso terapéutico , Infecciones por Citomegalovirus/tratamiento farmacológico , Infecciones por Citomegalovirus/inmunología , Huésped Inmunocomprometido/inmunología , Trasplante de Riñón/efectos adversos , Adolescente , Citomegalovirus/genética , Infecciones por Citomegalovirus/etiología , Farmacorresistencia Microbiana/genética , Femenino , Foscarnet/uso terapéutico , Ganciclovir/uso terapéutico , Humanos , Mutación
9.
Neuroscience ; 150(2): 459-66, 2007 Dec 05.
Artículo en Inglés | MEDLINE | ID: mdl-17997045

RESUMEN

We investigated using the mice role of nitric oxide synthase (NOS) in the spinal dorsal horn in herpetic and postherpetic pain, especially allodynia, which was induced by transdermal inoculation of the hind paw with herpes simplex virus type-1 (HSV-1). The virus inoculation induced NOS2 expression in the lumbar dorsal horn of mice with herpetic allodynia, but not postherpetic allodynia. There were no substantial alternations in the expression level of NOS1 at the herpetic and postherpetic stages. Herpetic allodynia was significantly inhibited by i.p. administration of the selective NOS2 inhibitor S-methylisothiourea, but not the selective NOS1 inhibitor 7-nitroindazole. NOS2 expression was observed around HSV-1 antigen-immunoreactive cells. On the other hand, postherpetic allodynia was significantly inhibited by i.p. administration of 7-nitroindazole, but not S-methylisothiourea. The activity of reduced nicotinamide adenine dinucleotide phosphate diaphorase, an index of NOS1 activity, significantly increased in the laminae I and II of the lumbar dorsal horn of mice with postherpetic allodynia, but not mice without postherpetic allodynia. The expression level of NOS1 mRNA in the dorsal root ganglia was similar between mice with and without postherpetic allodynia. The results suggest that herpetic and postherpetic allodynia is mediated by nitric oxide in the dorsal horn and that NOS2 and NOS1 are responsible for herpetic and postherpetic allodynia, respectively. It may be worth testing the effects of NOS2 and NOS1 inhibitors on herpetic pain and postherpetic neuralgia in human subjects, respectively.


Asunto(s)
Ganglios Espinales/enzimología , Neuralgia Posherpética/enzimología , Neuralgia Posherpética/fisiopatología , Óxido Nítrico Sintasa de Tipo II/metabolismo , Óxido Nítrico Sintasa de Tipo I/metabolismo , Óxido Nítrico/biosíntesis , Células del Asta Posterior/enzimología , Animales , Dihidrolipoamida Deshidrogenasa/metabolismo , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Femenino , Ganglios Espinales/fisiopatología , Ganglios Espinales/virología , Herpesvirus Humano 1/fisiología , Hiperalgesia/enzimología , Hiperalgesia/fisiopatología , Hiperalgesia/virología , Indazoles/farmacología , Isotiuronio/análogos & derivados , Isotiuronio/farmacología , Ratones , Ratones Endogámicos C57BL , Óxido Nítrico Sintasa de Tipo I/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo I/genética , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo II/genética , Nociceptores/enzimología , Nociceptores/fisiopatología , Nociceptores/virología , Células del Asta Posterior/fisiopatología , Células del Asta Posterior/virología , ARN Mensajero/metabolismo , Regulación hacia Arriba/fisiología
10.
Opt Express ; 15(2): 397-401, 2007 Jan 22.
Artículo en Inglés | MEDLINE | ID: mdl-19532256

RESUMEN

We demonstrated high-speed transmission at visible wavelengths over a 1 km photonic crystal fiber (PCF). We achieved a 1 Gbit/s transmission at 783 nm by using the direct modulation of a cost-effective Fabry-Perot laser diode (FP-LD). By employing the external modulation of the longitudinally single-mode grating-stabilized LD, we obtained the first penalty free 10 Gbit/s transmission at 780 nm.

11.
Drugs Today (Barc) ; 53(11): 573-584, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29451274

RESUMEN

Valacyclovir and famciclovir enabled successful systemic therapy for treating herpes simplex virus (HSV) and varicella zoster virus (VZV) infection by their phosphorylation with viral thymidine kinase. Helicase-primase inhibitors (HPIs) inhibit the progression of the replication fork, an initial step in DNA synthesis to separate the double strand into two single strands. The HPIs amenamevir and pritelivir have a novel mechanism of action, once-daily administration with nonrenal excretory characteristics, and clinical efficacy for genital herpes. Amenamevir exhibits anti-VZV and anti-HSV activity while pritelivir only has anti-HSV activity. A clinical trial of amenamevir for herpes zoster has been completed, and amenamevir has been licensed and successfully used in 20,000 patients with herpes zoster so far in Japan. We have characterized the features of the antiviral action of amenamevir and, unlike acyclovir, the drug's antiviral activity is not influenced by the viral replication cycle. Amenamevir is opening a new era of antiherpes therapy.


Asunto(s)
Antivirales/farmacología , Herpes Zóster/tratamiento farmacológico , Oxadiazoles/farmacología , Animales , ADN Helicasas/antagonistas & inhibidores , ADN Primasa/antagonistas & inhibidores , Farmacorresistencia Viral , Herpes Zóster/virología , Herpesvirus Humano 3/enzimología , Herpesvirus Humano 3/aislamiento & purificación , Humanos , Piridinas/farmacología , Sulfonamidas , Tiazoles/farmacología , Proteínas Virales/antagonistas & inhibidores
13.
Cancer Res ; 58(19): 4434-8, 1998 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-9766675

RESUMEN

We immunohistochemically analyzed the expression of double-stranded RNA-dependent protein kinase (PKR) using a monoclonal antibody, 71/10. Test samples included 64 human liver biopsies and 25 liver sections of rats inoculated with diethylnitrosamine. The PKR signals in human fatty livers and normal rat livers were minimum. Scoring signal intensity from 0-4, the average scores of chronic active (14 cases) and chronic persistent (6 cases) hepatitis associated with hepatitis virus C (HCV) were 2.8 and 2.0, respectively (P = 0.038). The stained cells were significantly more abundant in the periportal than centrilobular regions for both chronic active and persistent hepatitis (P < 0.001 each). The average score of liver cirrhosis associated with HCV was 1.9. Those scores of well-, moderately, and poorly differentiated hepatocellular carcinomas associated with HCV were 3.4, 2.1, and 0.3, respectively (P < 0.001 for each pair). Those scores of well- and poorly differentiated carcinomas associated with hepatitis virus B were 2.3 and 0.0, respectively (P < 0.001). The average score of rat carcinomas induced by diethylnitrosamine was 1.9. Morphologically, nuclei of the vast majority of PKR-positive cells looked not apoptotic. The ratio of PKR-positive cells to apoptotic cells by terminal transferase-mediated dUTP nick end labeling method was approximately 20 in hepatitis, and over 100 in well-differentiated carcinoma.


Asunto(s)
Carcinoma Hepatocelular/enzimología , Hepatitis C Crónica/enzimología , Neoplasias Hepáticas/enzimología , Hígado/enzimología , eIF-2 Quinasa/metabolismo , Animales , Anticuerpos Monoclonales , Apoptosis , Biopsia con Aguja , Carcinoma Hepatocelular/patología , Dietilnitrosamina/toxicidad , Hígado Graso/enzimología , Humanos , Inmunohistoquímica , Hígado/efectos de los fármacos , Hígado/patología , Cirrosis Hepática/enzimología , Cirrosis Hepática/patología , Neoplasias Hepáticas/patología , Neoplasias Hepáticas Experimentales/enzimología , Ratas , Células Tumorales Cultivadas
14.
Oncogene ; 19(29): 3225-34, 2000 Jul 06.
Artículo en Inglés | MEDLINE | ID: mdl-10918579

RESUMEN

Survivin is observed uniquely in tumor cells and developmental cells, which undergo either inappropriate or programmed cell growth. In the current study, we investigated the influence of Survivin on cell cycle. Overexpression of Survivin resulted in accelerated S phase shift, resistance to G1 arrest, and activated Cdk2/Cyclin E complex leading Rb phosphorylation. In addition, nuclear translocation of Survivin followed by an interaction with Cdk4 was detected. Interestingly, Survivin nuclear translocation coincided with S phase shift, and prevention of nuclear transport suppressed Survivin nuclear translocation and S phase shift. Further, we also observed that Survivin competitively interacted with the Cdk4/p16(INK4a) complex in a cell free system and in vivo. These results suggest that Survivin initiates the cell cycle entry as a result of nuclear translocation followed by an interaction with Cdk4.


Asunto(s)
Quinasas CDC2-CDC28 , Proteínas Portadoras/metabolismo , Ciclina E/metabolismo , Quinasas Ciclina-Dependientes/metabolismo , Proteínas Asociadas a Microtúbulos , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas/metabolismo , Proteínas Proto-Oncogénicas , Secuencia de Aminoácidos , Animales , Apoptosis , Unión Competitiva , Transporte Biológico , Ciclo Celular , Núcleo Celular/metabolismo , Quinasa 2 Dependiente de la Ciclina , Quinasa 4 Dependiente de la Ciclina , Inhibidor p16 de la Quinasa Dependiente de Ciclina , Activación Enzimática , Humanos , Proteínas Inhibidoras de la Apoptosis , Datos de Secuencia Molecular , Proteínas de Neoplasias , Pruebas de Neutralización , Fosforilación , Proteínas/genética , Proteínas/inmunología , Conejos , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Proteínas Recombinantes de Fusión/metabolismo , Proteína de Retinoblastoma/metabolismo , Survivin , Células Tumorales Cultivadas
15.
Oncogene ; 19(10): 1346-53, 2000 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-10713676

RESUMEN

Caspase 3 is an essential death factor for the Fas-mediated cell death, and its inactivation in cells is initiated by an interaction with p21 on mitochondria or with IAP family member ILP. Survivin is also a member of IAP family and is specifically expressed during embryogenesis and in tumor cells and suppresses cell death signaling. In our current study, we demonstrated that Survivin translocation into the nucleus is dependent on Fas stimulation and cell proliferation. Survivin also interacts with the cell cycle regulator Cdk4, leading to Cdk2/Cyclin E activation and Rb phosphorylation. As a result of Survivin/Cdk4 complex formation, p21 is released from its complex with Cdk4 and interacts with mitochondrial procaspase 3 to suppress Fas-mediated cell death. Here, we propose that Survivin supports procaspase 3/p21 complex formation as a result of interaction with Cdk4 resulting in suppression of cell death signaling.


Asunto(s)
Caspasas/metabolismo , Muerte Celular , Quinasas Ciclina-Dependientes/metabolismo , Ciclinas/metabolismo , Proteínas Asociadas a Microtúbulos , Proteínas/metabolismo , Proteínas Proto-Oncogénicas , Receptor fas/metabolismo , Caspasa 3 , Supervivencia Celular , Quinasa 4 Dependiente de la Ciclina , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Precursores Enzimáticos/metabolismo , Proteínas Inhibidoras de la Apoptosis , Modelos Biológicos , Proteínas de Neoplasias , Unión Proteica , Survivin
16.
Biochim Biophys Acta ; 1517(3): 424-9, 2001 Feb 16.
Artículo en Inglés | MEDLINE | ID: mdl-11342221

RESUMEN

We have cloned and sequenced a 5 kb genomic fragment in the 5'-flanking region of the human myosin phosphatase target subunit 1. The transcription initiation site (+1) was 268 bp upstream from the translation start site. In this promoter there are no canonical TATA or CAAT box elements but there is a high GC-rich sequence. Basal promoter activity was due to the GC-rich region that contained one Sp1 transcription factor binding site, thus demonstrating that the MYPT1 gene is a housekeeping gene. Luciferase reporter assays showed the presence of two regions for positive elements and one for a negative element.


Asunto(s)
Fosfoproteínas Fosfatasas/genética , Secuencia de Bases , Sitios de Unión , Células Cultivadas , Clonación Molecular , ADN/genética , ADN/metabolismo , Cartilla de ADN/genética , Células HeLa , Humanos , Luciferasas/genética , Datos de Secuencia Molecular , Fosfatasa de Miosina de Cadena Ligera , Fosfoproteínas Fosfatasas/química , Regiones Promotoras Genéticas , Subunidades de Proteína , Factor de Transcripción Sp1/metabolismo , Transcripción Genética
17.
J Am Coll Cardiol ; 28(6): 1610-5, 1996 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-8917278

RESUMEN

OBJECTIVES: This study sought to investigate the effects of nitric oxide inhibition in a murine model of coxsackievirus B3 myocarditis. BACKGROUND: Little is known about the contribution of nitric oxide to the pathophysiology of myocarditis. METHODS: Antiviral activity was tested in vitro using nitric oxide inhibition by treatment with activated macrophages of NG-nitro-L-arginine methyl ester. In the in vivo experiments, NG-nitro-L-arginine methyl ester and NG-nitro-D-arginine methyl ester (both at 100 micrograms/ml) were administered to C3H/He mice early (days 0 to 14) and late (days 14 to 35) after infection with coxsackievirus B3. RESULTS: In the in vitro experiments with interferon-gamma- and lipopolysaccharide-induced activated murine macrophages, treatment with the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester, but not its inactive enantiomer NG-nitro-D-arginine methyl ester, restored coxsackievirus B3 titers. In the in vivo experiments in the early treatment group, myocardial virus titers were higher in NG-nitro-L-arginine methyl ester-treated than infected untreated animals, and both inflammatory cell infiltration and necrosis were more severe. In the late treatment group, more severe necrosis and more dense myocardial and perivascular fibrosis were observed in NG-nitro-L-arginine methyl ester-treated than in infected untreated animals. NG-Nitro-D-arginine methyl ester administration was ineffective. CONCLUSIONS: Nitric oxide inhibition increases myocardial virus titers, resulting in the aggravation of cardiac pathology in the early stage of coxsackievirus B3 myocarditis. In the late stage, it induces more severe cardiomyopathic lesions. Nitric oxide plays a defensive role in the pathogenesis of coxsackievirus B3 myocarditis.


Asunto(s)
Infecciones por Coxsackievirus/virología , Enterovirus Humano B/fisiología , Miocarditis/virología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/fisiología , Replicación Viral , Animales , Infecciones por Coxsackievirus/tratamiento farmacológico , Infecciones por Coxsackievirus/enzimología , Inhibidores Enzimáticos/uso terapéutico , Macrófagos/virología , Ratones , Miocarditis/tratamiento farmacológico , Miocarditis/enzimología , NG-Nitroarginina Metil Éster/uso terapéutico , Viremia/tratamiento farmacológico , Viremia/enzimología
18.
J Mol Biol ; 245(2): 180-94, 1995 Jan 13.
Artículo en Inglés | MEDLINE | ID: mdl-7799434

RESUMEN

Trifluoroethanol (TFE) is known to stabilize the alpha-helical structure in proteins and their fragments. However, the relationship between the TFE-induced structures and the native structure is not clear. Here we show that beta-lactoglobulin, which consists predominantly of beta-sheets, exhibited a markedly high propensity to form an alpha-helical structure in the presence of TFE, as measured by far-UV circular dichroism. A cooperative transformation from the beta-sheet structure to an alpha-helical structure occurred at a TFE concentration between 10% and 20%. These results were in contrast to a gradual beta-sheet to alpha-helix transition of the constant fragment of the immunoglobulin light chain, which is also a beta-sheet protein. To understand the significance of the high helical propensity of beta-lactoglobulin, we measured the TFE-induced conformational transition of more than 20 proteins of various secondary structural types. Whereas the alpha-helical proteins showed a propensity to form an extensive helical structure in TFE, the helical propensity of proteins with a low helical content in the native state varied. The helical content in TFE was correlated more with the helical content predicted by a secondary structure prediction than with the helical content of the native structure, suggesting that the stability of the helical structure in TFE is determined by local interactions between nearby amino acid residues. Our results suggest that an alpha-helical intermediate can accumulate during the refolding process of beta-lactoglobulin and that a hierarchical model of protein folding is not necessarily true for some beta-sheet proteins including beta-lactoglobulin.


Asunto(s)
Lactoglobulinas/química , Lactoglobulinas/efectos de los fármacos , Pliegue de Proteína , Estructura Secundaria de Proteína/efectos de los fármacos , Trifluoroetanol/farmacología , Animales , Apoproteínas/química , Apoproteínas/efectos de los fármacos , Grupo Citocromo c/química , Grupo Citocromo c/efectos de los fármacos , Regiones Constantes de Inmunoglobulina/química , Regiones Constantes de Inmunoglobulina/efectos de los fármacos , Cadenas Ligeras de Inmunoglobulina/química , Cadenas Ligeras de Inmunoglobulina/efectos de los fármacos , Muramidasa/química , Muramidasa/efectos de los fármacos , Mioglobina/química , Mioglobina/efectos de los fármacos
19.
Cardiovasc Res ; 29(1): 80-4, 1995 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-7895243

RESUMEN

OBJECTIVE: The aim was to test the therapeutic efficacy of naloxone, an opiate receptor antagonist, upon murine coxsackievirus B3 myocarditis with the analysis of neurohumoral kinetics. METHODS: Two week old C3H/He mice were inoculated with 10(3) plaque forming units of coxsackie B3 virus. Naloxone, 1 mg.kg-1.d-1, was given intraperitoneally daily on days 0-14 in experiment I, and on days 14-28 in experiment II. The treated groups were compared to infected controls in each experiment. For the analysis of the endogenous opiate and neurohumoral system, plasma beta endorphin and catecholamines were measured. RESULTS: In experiment I, survival rate did not differ significantly between naloxone treated and untreated groups (11/15 v 8/15, p = NS). Pathological scores (infiltration and necrosis), myocardial virus titres, and plasma beta endorphin and catecholamine concentrations did not differ significantly between the two groups. In experiment II, survival rate (13/16 v 6/14, P < 0.05) was higher and cardiac pathology was less severe, with a lower incidence of congestive heart failure, in naloxone than in controls groups. In addition, beta endorphin and noradrenaline were significantly increased in the naloxone group compared to the control. CONCLUSIONS: The endogenous opiate system is activated in congestive heart failure caused by severe myocardial damage in murine coxsackie B3 myocarditis, where an associated limitation of the sympathetic system may be present. Naloxone is beneficial in congestive heart failure caused by coxsackie B3 myocarditis because of its neurohumoral modulating effect.


Asunto(s)
Infecciones por Coxsackievirus/tratamiento farmacológico , Miocarditis/virología , Naloxona/uso terapéutico , Animales , Infecciones por Coxsackievirus/sangre , Infecciones por Coxsackievirus/patología , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/tratamiento farmacológico , Insuficiencia Cardíaca/patología , Insuficiencia Cardíaca/virología , Masculino , Ratones , Ratones Endogámicos C3H , Miocarditis/sangre , Miocarditis/tratamiento farmacológico , Miocarditis/patología , Miocardio/patología , Norepinefrina/sangre , Tasa de Supervivencia , betaendorfina/sangre
20.
Cardiovasc Res ; 27(6): 957-61, 1993 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8221785

RESUMEN

OBJECTIVE: The aim was to test the role of oxygen derived free radicals in the development of myocarditis. This involved investigating the effects of polyethylene glycol conjugated superoxide dismutase (PEG-SOD, an enzyme catalysing the conversion of O2.- to H2O2) and polyethylene glycol conjugated catalase (PEG-catalase, accelerating the reaction of H2O2 to H2O and O2) upon coxsackievirus B3 (CB3) myocarditis. METHODS: Two week old male C3H/He mice were inoculated intraperitoneally with 10(3) plaque forming units of CB3. PEG-SOD, 1 x 10(3) U.kg-1 x d-1, and PEG-SOD, 1 x 10(3) U.kg-1 x d-1, plus PEG-catalase, 1 x 10(3) U.kg-1 x d-1, were injected subcutaneously daily on days 0 to 14. Treated groups were compared to the infected control. RESULTS: On day 7, there were no significant differences in pathological scores among the three groups. On day 14, the cellular infiltration, myocardial necrosis, and calcification scores were significantly lower in the PEG-SOD group and the PEG-SOD plus PEG-catalase group than in the control. There were no significant differences in pathological scores between the PEG-SOD group and the PEG-SOD plus PEG-catalase group. There were no differences in the myocardial virus titres on day 7 among the three groups. On day 14, virus was not detected from the myocardium in any of the three groups. CONCLUSIONS: The results suggest that superoxide anion is mostly responsible for myocyte injury in CB3 myocarditis in mice, and that hydrogen peroxide formed as a result of dismutation of superoxide anion may not play a significant role in the development of myocarditis. Superoxide anion is one of the most important factors in free radical mediated injury in CB3 myocarditis in mice and the administration of PEG-SOD alone has therapeutic potential in clinical CB3 myocarditis.


Asunto(s)
Catalasa/farmacología , Infecciones por Coxsackievirus/metabolismo , Enterovirus Humano B , Miocarditis/etiología , Polietilenglicoles/farmacología , Superóxido Dismutasa/farmacología , Animales , Catalasa/metabolismo , Infecciones por Coxsackievirus/patología , Radicales Libres/metabolismo , Corazón/microbiología , Masculino , Ratones , Ratones Endogámicos C3H , Miocarditis/metabolismo , Miocarditis/microbiología , Miocarditis/patología , Miocarditis/prevención & control , Miocardio/patología , Polietilenglicoles/metabolismo , Superóxido Dismutasa/metabolismo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda